论文部分内容阅读
目的 探讨含铂类方案治疗晚期非小细胞肺癌(NSCLC)的长期生存率及其预后因素。方法 自1990年3月至1999年6月,我们以含铂类方案治疗了123例Ⅲ_A～Ⅳ期NSCLC,对于生存期>2年者,我们研究了其生存特点及预后因素。结果 13例(10.6％)生存期>2年,3例(2.4％)生存期>5年。多元化分析结果显示:分期、行为状态、转移病灶数、合并肺部疾病 为影响长期生存的预后因素。结论 含铂类联合化疗方案治疗晚期NSCLC的2年生存率为10.6％,分期、行为状态、转移病灶数、合并肺部疾病是影响NSCLC长期生存的预后因素。
Objective To investigate the long-term survival rate and prognostic factors of patients with advanced non-small cell lung cancer (NSCLC) with platinum-based regimen. Methods From March 1990 to June 1999, we treated 123 cases of stage III_A~IV NSCLC with platinum-containing regimen. We studied survival characteristics and prognostic factors for those with a survival period of >2 years. Results The survival time of 13 patients (10.6%) was more than 2 years, and the survival time of 3 patients (2.4%) was more than 5 years. The results of diversification analysis showed that staging, behavioral status, number of metastatic lesions, and combined lung disease were prognostic factors that affected long-term survival. Conclusions The 2-year survival rate of platinum-based combination chemotherapy regimen for advanced NSCLC is 10.6%. The staging, behavioral status, number of metastatic lesions, and pulmonary disease are prognostic factors affecting long-term survival of NSCLC.